Spots Global Cancer Trial Database for extrahepatic cholangiocarcinoma
Every month we try and update this database with for extrahepatic cholangiocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | NCT04561453 | Biliary Tract C... Cholangiocarcin... Gallbladder Can... Intrahepatic Ch... Perihilar Chola... Extrahepatic Ch... Hilar Cholangio... Distal Bile Duc... | Multi-Platform ... | 18 Years - | University of Washington | |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer | NCT04333927 | Biliary Tract C... Extrahepatic Ch... Gallbladder Can... | Chemotherapy Observation Immunotherapy Radiotherapy | 18 Years - 70 Years | Sun Yat-sen University | |
| An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma | NCT05448183 | Extrahepatic Ch... | Toripalimab, Ge... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 | NCT05518071 | Pancreas Adenoc... Cholangiocarcin... | CRGD-ZW800-1 Intraoperative ... | 18 Years - | Leiden University Medical Center | |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | NCT05009953 | Advanced Biliar... Intrahepatic Ch... Extrahepatic Ch... Gallbladder Car... | Irinotecan Lipo... SG001 Fluorouracil Leucovorin | 18 Years - | CSPC Ouyi Pharmaceutical Co., Ltd. | |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | NCT03267940 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Gallbladder Ade... | PEGPH20 CIS GEM Atezolizumab | 18 Years - | Halozyme Therapeutics | |
| Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | NCT04301999 | Cholangiocarcin... | Photodynamic th... radiofrequency ... | 18 Years - 80 Years | First People's Hospital of Hangzhou | |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | NCT05712356 | Cholangiocarcin... Gallbladder Can... Gallbladder Car... Intrahepatic Ch... Extrahepatic Ch... Bile Duct Cance... Gall Bladder Ca... Gall Bladder Ca... | LSTA1 Durvalumab Cisplatin Gemcitabine FOLFOX regimen Placebo | 18 Years - | Lisata Therapeutics, Inc. | |
| Clinical Effect and Safety of PDT and RFA for Unresectable EHCC | NCT04301999 | Cholangiocarcin... | Photodynamic th... radiofrequency ... | 18 Years - 80 Years | First People's Hospital of Hangzhou | |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | NCT03929666 | HER2-expressing... | ZW25 (Zanidatam... Capecitabine Cisplatin Fluorouracil Leucovorin Oxaliplatin Bevacizumab Gemcitabine | 18 Years - | Jazz Pharmaceuticals | |
| Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma | NCT05233293 | Extrahepatic Ch... Malignant Bilia... | Spyglass + RFA Cytobrush + RFA | 18 Years - | First People's Hospital of Hangzhou | |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) | NCT06101277 | Esophageal Canc... Small Bowel Can... Gastroesophagea... Gastric Cancer Colorectal Canc... Appendiceal Can... Biliary Cancer Gall Bladder Ca... Intrahepatic Ch... Extrahepatic Ch... Oligoprogressiv... | Ablative local ... | 18 Years - | University of California, Davis | |
| Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma | NCT05233293 | Extrahepatic Ch... Malignant Bilia... | Spyglass + RFA Cytobrush + RFA | 18 Years - | First People's Hospital of Hangzhou | |
| Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | NCT01954745 | Bile Duct Cance... Intrahepatic Ch... Cholangiocarcin... | Cabozantinib | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
